Literature DB >> 32991394

Cardiac Manifestations of Systemic Lupus Erythematous: An Overview of the Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology and Treatment Options.

Nicole K Zagelbaum Ward1, Carlos Linares-Koloffon2, Alba Posligua3, Liliya Gandrabur3, Woo Young Kim3, Kirk Sperber3, Amy Wasserman3, Julia Ash3.   

Abstract

Systemic lupus erythematosus (SLE) is a complex connective tissue disease that can potentially affect every organ of the human body. In some cases, SLE may present with diverse cardiac manifestations including pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias. Heart disease in SLE is associated with increased morbidity and mortality. It is unclear whether traditional treatments for coronary artery disease significantly impact mortality in this population. Current therapeutic agents for SLE include glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and B cell-directed therapies. This article will provide a comprehensive review and update on this important disease state.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 32991394     DOI: 10.1097/CRD.0000000000000358

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  2 in total

1.  TLR7 Activation Accelerates Cardiovascular Pathology in a Mouse Model of Lupus.

Authors:  Ahmed S Elshikha; Xiang Yu Teng; Nathalie Kanda; Wei Li; Seung-Chul Choi; Georges Abboud; Morgan Terrell; Kristianna Fredenburg; Laurence Morel
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

2.  Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.

Authors:  Enrico Ammirati; Emanuele Bizzi; Giacomo Veronese; Matthieu Groh; Caroline M Van de Heyning; Jukka Lehtonen; Marc Pineton de Chambrun; Alberto Cereda; Chiara Picchi; Lucia Trotta; Javid J Moslehi; Antonio Brucato
Journal:  Front Med (Lausanne)       Date:  2022-03-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.